Market Overview

UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Complete Phase 3 Eye Drug Data

Share:
Related REGN
Benzinga's Top Upgrades, Downgrades For February 13, 2017
The Market In 5 Minutes: Hello... Can You Hear Me?
What Makes Amgen A Compelling Buy In 2017? (Seeking Alpha)

In a report published Monday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), and raised the price target from $329.00 to $355.00.

In the report, Goldman Sachs noted, “REGN reported complete Phase 3 data for key eye drug, Eylea for a new indication (DME, vision loss due to diabetes) at the Retina Society conference. The data were in line with our expectations and we anticipate they will support approval for a broader label and drive uptake/growth.”

Regeneron Pharmaceuticals closed on Friday at $305.65.

Latest Ratings for REGN

DateFirmActionFromTo
Feb 2017PiperJaffrayUpgradesNeutralOverweight
Dec 2016BMO CapitalInitiates Coverage OnMarket Perform
Dec 2016BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Goldman Sachs Terence FlynnAnalyst Color Price Target Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!